Lymphatic filariasis, commonly known as elephantiasis, is a parasitic disease caused by the transmission of thread-like nematode worms of the family Filariidae. The two main species responsible for the disease are Wuchereria bancrofti and Brugia malayi. It is primarily transmitted to humans through the bite of infected female mosquitoes, mainly from the genera Culex, Anopheles, and Aedes. Infection with filarial nematodes remains endemic in several countries worldwide and these infections are commonly associated with severe diseases. Of the estimated 120 million people affected by this disease and one-third live in India. W. bancrofti accounts for ~90% of the disease burden while B. malayi contributes the remaining ~10%. The elimination of lymphatic filariasis relies on mass drug administration (MDA) for the entire population at risk to stop disease transmission and prevent infectious morbidity. WHO recommends the use of annual medication in combination with the triple drug ivermectin therapy. The aim and objective of this article is to compare the efficacy and safety of triple drug versus double drug therapy for the eradication of onchocerciasis (LF) along with the status of lymphatic filariasis in India.